Adam Kinney Hiett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam Kinney Hiett has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Jiri Sonek
Fetal Medicine Foundation USA, Dayton, OH, USA
3 shared publications Brenda Garcia Lopez
BioFluidica, Inc. San Diego California USA
1 shared publicationDylan Dufek
BioFluidica, Inc. San Diego California USA
1 shared publicationJanet Dickerson
BioFluidica, Inc. San Diego California USA
1 shared publicationJennifer Barber‐Singh
BioFluidica, Inc. San Diego California USA
1 shared publicationJiri D. Sonek
Department of Obstetrics and Gynecology, Wright State University, Boonshoft School of Medicine, Dayton, OH
1 shared publication
Latest Publications
- 4 December 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 234 (6) , e237
Management of preterm prelabor rupture of membranes based on the amniocentesis information
- 4 December 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 234 (6) , e237
Management of preterm prelabor rupture of membranes based on the amniocentesis information
- 28 September 2021
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (13) , 1701-1708
Identification of fetal aneuploidy with dual‐probe fluorescence in situ hybridization analysis in circulating trophoblasts after enrichment using a high‐sensitivity microfluidic platform
Objective To evaluate a microfluidics-based positive selection technology for isolating circulating trophoblasts (CTs) from peripheral blood of women whose pregnancies are affected by aneuploidy and to evaluate fetal karyotype using fluorescence in situ hybridization (FISH). Method Ten 18-ml samples of peripheral blood were collected consecutively from pregnant women whose fetus was affected by aneuploidy. A preservation buffer was added, and the specimens were shipped overnight to the testing laboratory at ambient temperature. The specimen was infused into the fully automated microfluidics-based LiquidScan® instrument without pre-processing. This instrument contains microfluidic chips, which are coated with antibodies (anti-huEpCAM and a proprietary antibody mixture) specific to CT surface epitopes. FISH analysis was performed on the enriched cells. Results Fetal aneuploidy evaluated included trisomy 21 (n = 3), trisomy 18 (n = 1), trisomy 13 (n = 1), monosomy X (n = 3), and triploidy (n = 1). CTs for analysis by FISH were identified in all samples. The average number of mononucleate cells per 1 ml of whole blood was 2.11 (range 0.38–4.63) overall and was 2.67 (range 1.13–4.63) using the proprietary combination of antibodies. FISH results were concordant with the aneuploidy based on other testing in all cases. Multinucleate cells were searched for and identified in the last seven samples (average number: 0.84/1 ml). Conclusions Our study demonstrates that the LiquidScan®, a high-sensitivity microfluidic platform, can enrich circulating trophoblasts (mononucleate and multinucleate). FISH can then be used to detect fetal aneuploidy.
- 28 September 2021
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (13) , 1701-1708
Identification of fetal aneuploidy with dual‐probe fluorescence in situ hybridization analysis in circulating trophoblasts after enrichment using a high‐sensitivity microfluidic platform
Objective To evaluate a microfluidics-based positive selection technology for isolating circulating trophoblasts (CTs) from peripheral blood of women whose pregnancies are affected by aneuploidy and to evaluate fetal karyotype using fluorescence in situ hybridization (FISH). Method Ten 18-ml samples of peripheral blood were collected consecutively from pregnant women whose fetus was affected by aneuploidy. A preservation buffer was added, and the specimens were shipped overnight to the testing laboratory at ambient temperature. The specimen was infused into the fully automated microfluidics-based LiquidScan® instrument without pre-processing. This instrument contains microfluidic chips, which are coated with antibodies (anti-huEpCAM and a proprietary antibody mixture) specific to CT surface epitopes. FISH analysis was performed on the enriched cells. Results Fetal aneuploidy evaluated included trisomy 21 (n = 3), trisomy 18 (n = 1), trisomy 13 (n = 1), monosomy X (n = 3), and triploidy (n = 1). CTs for analysis by FISH were identified in all samples. The average number of mononucleate cells per 1 ml of whole blood was 2.11 (range 0.38–4.63) overall and was 2.67 (range 1.13–4.63) using the proprietary combination of antibodies. FISH results were concordant with the aneuploidy based on other testing in all cases. Multinucleate cells were searched for and identified in the last seven samples (average number: 0.84/1 ml). Conclusions Our study demonstrates that the LiquidScan®, a high-sensitivity microfluidic platform, can enrich circulating trophoblasts (mononucleate and multinucleate). FISH can then be used to detect fetal aneuploidy.
- Top Cited Papers
- 17 September 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 59 (5) , 668-676
Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O‐RADS in differentiating between benign and malignant adnexal lesions in North American women
Objectives: To apply the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), the IOTA Simple Rules risk assessment (SRR), the IOTA Assessment of Different NEoplasias in the adneXa (ADNEX) model and the Ovarian‐Adnexal Reporting and Data System (O‐RADS) in the same cohort of North American patients and to compare their performance in preoperative discrimination between benign and malignant adnexal lesions.Methods: This was a single‐center diagnostic accuracy study, performed between March 2018 and February 2021, which included 150 women with an adnexal lesion. Using the ADNEX model, lesions were classified prospectively, whereas the SR, SRR assessment and O‐RADS were applied retrospectively. Surgery with histological analysis was performed within 6 months of the ultrasound exam. Sensitivity and specificity were determined for each testing modality and the performance of the different modalities was compared.Results: Of the 150 women, 110 (73.3%) had a benign ovarian tumor and 40 (26.7%) had a malignant tumor. The mean risk of malignancy generated by the ADNEX model without CA 125 was significantly higher in malignant vs benign lesions (63.3% vs 11.8%) and the area under the receiver‐operating‐characteristics curve (AUC) of the ADNEX model for differentiating between benign and malignant adnexal masses at the time of ultrasound examination was 0.937. The mean risk of malignancy generated by SRR assessment was also significantly higher in malignant vs benign lesions (74.1% vs 15.9%) and the AUC was 0.941. To compare the ADNEX model, SRR assessment and O‐RADS, the malignancy risk threshold was set at ≥ 10%. This cut‐off differentiates O‐RADS low‐risk categories (Category ≤ 3) from intermediate‐to‐high‐risk categories (Categories 4 and 5). At this cut‐off, the sensitivity of the ADNEX model was 97.5% (95% CI, 85.3%–99.9%) and the specificity was 63.6% (95% CI, 53.9%–72.4%), and, for the SRR model, the sensitivity was 100% (95% CI, 89.1%–100%) and the specificity was 51.8% (95% CI, 42.1%–61.4%). In the 113 cases to which the SR could be applied, the sensitivity was 100% (95% CI, 81.5%–100%) and the specificity was 95.6% (95% CI, 88.5%–98.6%). If the remaining 37 cases, which were inconclusive under SR, were designated ‘malignant’, the sensitivity remained at 100% but the specificity was reduced to 79.1% (95% CI, 70.1%–86.0%). The 150 cases fell into the following O‐RADS categories: 17 (11.3%) lesions in Category 2, 34 (22.7%) in Category 3, 66 (44.0%) in Category 4 and 33 (22.0%) in Category 5. There were no histologically proven malignant lesions in Category 2 or 3. There were 14 malignant lesions in Category 4 and 26 in Category 5. The sensitivity of O‐RADS using a malignancy risk threshold of ≥ 10% was 100% (95% CI, 89.1%–100.0%) and the specificity was 46.4% (95% CI, 36.9%–56.1%).Conclusions: When IOTA terms and techniques are used, the performance of IOTA models in a North American patient population is in line with published IOTA results in other populations. The IOTA SR, SRR assessment and ADNEX model and O‐RADS have similar sensitivity in the preoperative discrimination of malignant from benign pelvic tumors; however, the IOTA models have higher specificity and the algorithm does not require the use of magnetic resonance imaging. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
- 17 September 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 59 (5) , 668-676
Top Cited PapersPerformance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O‐RADS in differentiating between benign and malignant adnexal lesions in North American women
Objectives: To apply the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), the IOTA Simple Rules risk assessment (SRR), the IOTA Assessment of Different NEoplasias in the adneXa (ADNEX) model and the Ovarian‐Adnexal Reporting and Data System (O‐RADS) in the same cohort of North American patients and to compare their performance in preoperative discrimination between benign and malignant adnexal lesions.Methods: This was a single‐center diagnostic accuracy study, performed between March 2018 and February 2021, which included 150 women with an adnexal lesion. Using the ADNEX model, lesions were classified prospectively, whereas the SR, SRR assessment and O‐RADS were applied retrospectively. Surgery with histological analysis was performed within 6 months of the ultrasound exam. Sensitivity and specificity were determined for each testing modality and the performance of the different modalities was compared.Results: Of the 150 women, 110 (73.3%) had a benign ovarian tumor and 40 (26.7%) had a malignant tumor. The mean risk of malignancy generated by the ADNEX model without CA 125 was significantly higher in malignant vs benign lesions (63.3% vs 11.8%) and the area under the receiver‐operating‐characteristics curve (AUC) of the ADNEX model for differentiating between benign and malignant adnexal masses at the time of ultrasound examination was 0.937. The mean risk of malignancy generated by SRR assessment was also significantly higher in malignant vs benign lesions (74.1% vs 15.9%) and the AUC was 0.941. To compare the ADNEX model, SRR assessment and O‐RADS, the malignancy risk threshold was set at ≥ 10%. This cut‐off differentiates O‐RADS low‐risk categories (Category ≤ 3) from intermediate‐to‐high‐risk categories (Categories 4 and 5). At this cut‐off, the sensitivity of the ADNEX model was 97.5% (95% CI, 85.3%–99.9%) and the specificity was 63.6% (95% CI, 53.9%–72.4%), and, for the SRR model, the sensitivity was 100% (95% CI, 89.1%–100%) and the specificity was 51.8% (95% CI, 42.1%–61.4%). In the 113 cases to which the SR could be applied, the sensitivity was 100% (95% CI, 81.5%–100%) and the specificity was 95.6% (95% CI, 88.5%–98.6%). If the remaining 37 cases, which were inconclusive under SR, were designated ‘malignant’, the sensitivity remained at 100% but the specificity was reduced to 79.1% (95% CI, 70.1%–86.0%). The 150 cases fell into the following O‐RADS categories: 17 (11.3%) lesions in Category 2, 34 (22.7%) in Category 3, 66 (44.0%) in Category 4 and 33 (22.0%) in Category 5. There were no histologically proven malignant lesions in Category 2 or 3. There were 14 malignant lesions in Category 4 and 26 in Category 5. The sensitivity of O‐RADS using a malignancy risk threshold of ≥ 10% was 100% (95% CI, 89.1%–100.0%) and the specificity was 46.4% (95% CI, 36.9%–56.1%).Conclusions: When IOTA terms and techniques are used, the performance of IOTA models in a North American patient population is in line with published IOTA results in other populations. The IOTA SR, SRR assessment and ADNEX model and O‐RADS have similar sensitivity in the preoperative discrimination of malignant from benign pelvic tumors; however, the IOTA models have higher specificity and the algorithm does not require the use of magnetic resonance imaging. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
- 1 January 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (1) , S333
680: Evaluation of the prefrontal space ratio for the prenatal diagnosis of micrognathia
- 1 January 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (1) , S333
680: Evaluation of the prefrontal space ratio for the prenatal diagnosis of micrognathia